174 related articles for article (PubMed ID: 11383939)
1. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis.
Keles MS; Taysi S; Sen N; Aksoy H; Akçay F
Can J Neurol Sci; 2001 May; 28(2):141-3. PubMed ID: 11383939
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant potential and transferrin, ceruloplasmin, and lipid peroxidation levels in women with preeclampsia.
Aksoy H; Taysi S; Altinkaynak K; Bakan E; Bakan N; Kumtepe Y
J Investig Med; 2003 Sep; 51(5):284-7. PubMed ID: 14577518
[TBL] [Abstract][Full Text] [Related]
3. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients.
Hunter MI; Nlemadim BC; Davidson DL
Neurochem Res; 1985 Dec; 10(12):1645-52. PubMed ID: 4088434
[TBL] [Abstract][Full Text] [Related]
4. The effect of corticosteroids on serum and cerebrospinal fluid nitric oxide levels in multiple sclerosis.
Sait Keles M; Taysi S; Aksoy H; Sen N; Polat F; Akcay F
Clin Chem Lab Med; 2001 Sep; 39(9):827-9. PubMed ID: 11601681
[TBL] [Abstract][Full Text] [Related]
5. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients.
Ghabaee M; Jabedari B; Al-E-Eshagh N; Ghaffarpour M; Asadi F
Int J Neurosci; 2010 Apr; 120(4):301-4. PubMed ID: 20374079
[TBL] [Abstract][Full Text] [Related]
6. Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients.
Adamczyk-Sowa M; Sowa P; Pierzchala K; Polaniak R; Labuz-Roszak B
J Physiol Pharmacol; 2012 Dec; 63(6):683-90. PubMed ID: 23388485
[TBL] [Abstract][Full Text] [Related]
7. Changes in levels of oxidative stress markers and some neuronal enzyme activities in cerebrospinal fluid of multiple sclerosis patients.
Bartova R; Petrlenicova D; Oresanska K; Prochazkova L; Liska B; Turecky L; Durfinova M
Neuro Endocrinol Lett; 2016; 37(2):102-6. PubMed ID: 27179571
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis.
Wang P; Xie K; Wang C; Bi J
Eur Neurol; 2014; 72(3-4):249-54. PubMed ID: 25277682
[TBL] [Abstract][Full Text] [Related]
9. [State of antioxidant system in patients with multiple sclerosis during therapy].
Smirnova LP; Krotenko NV; Grishko EV; Krotenko NM; Alifirova VM; Ivanova SA
Biomed Khim; 2011; 57(6):661-70. PubMed ID: 22359923
[TBL] [Abstract][Full Text] [Related]
10. Copper and ceruloplasmin dyshomeostasis in serum and cerebrospinal fluid of multiple sclerosis subjects.
De Riccardis L; Buccolieri A; Muci M; Pitotti E; De Robertis F; Trianni G; Manno D; Maffia M
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1828-1838. PubMed ID: 29524632
[TBL] [Abstract][Full Text] [Related]
11. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus.
Memişoğullari R; Bakan E
J Diabetes Complications; 2004; 18(4):193-7. PubMed ID: 15207835
[TBL] [Abstract][Full Text] [Related]
12. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients.
Zeman D; Adam P; Kalistová H; Sobek O; Kelbich P; Andel J; Andel M
Acta Neurol Scand; 2000 Feb; 101(2):89-94. PubMed ID: 10685854
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
Trentini A; Castellazzi M; Romani A; Squerzanti M; Baldi E; Caniatti ML; Pugliatti M; Granieri E; Fainardi E; Bellini T; Cervellati C
J Neurol Sci; 2017 Jun; 377():133-136. PubMed ID: 28477683
[TBL] [Abstract][Full Text] [Related]
14. Lipid Peroxidation and Antioxidant Consumption as Early Markers of Neurosurgery-Related Brain Injury in Children.
Piastra M; Caresta E; Massimi L; Picconi E; Luca E; Morena TC; Conti G; Eaton S
Neurocrit Care; 2020 Aug; 33(1):124-131. PubMed ID: 31696410
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone.
Franciotta D; Piccolo G; Zardini E; Bergamaschi R; Cosi V
Acta Neurol Scand; 1997 May; 95(5):275-9. PubMed ID: 9188901
[TBL] [Abstract][Full Text] [Related]
16. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis.
Calabrese V; Raffaele R; Cosentino E; Rizza V
Int J Clin Pharmacol Res; 1994; 14(4):119-23. PubMed ID: 7607784
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha and its soluble receptors in plasma and cerebrospinal fluid of multiple sclerosis patients treated with methylprednisolone.
Franciotta D; Bergamaschi R; Martino G; Zardini E; Desina G; Cosi V
Eur Cytokine Netw; 1999 Sep; 10(3):431-6. PubMed ID: 10477400
[TBL] [Abstract][Full Text] [Related]
18. Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy.
Mitosek-Szewczyk K; Gordon-Krajcer W; Walendzik P; Stelmasiak Z
Folia Neuropathol; 2010; 48(2):116-22. PubMed ID: 20602292
[TBL] [Abstract][Full Text] [Related]
19. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients.
Al-Chalabi BM; Thanoon IA; Ahmed FA
Neuropsychobiology; 2009; 59(1):8-11. PubMed ID: 19221442
[TBL] [Abstract][Full Text] [Related]
20. Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.
Adamczyk-Sowa M; Sowa P; Mucha S; Zostawa J; Mazur B; Owczarek M; Pierzchała K
Med Sci Monit; 2016 Jul; 22():2484-91. PubMed ID: 27420299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
